临床药师参与1例滤泡性淋巴瘤合并丙型肝炎患者免疫化疗方案制订的病例分析
x

请在关注微信后,向客服人员索取文件

篇名: 临床药师参与1例滤泡性淋巴瘤合并丙型肝炎患者免疫化疗方案制订的病例分析
TITLE:
摘要: 目的:探讨临床药师在滤泡性淋巴瘤合并丙型肝炎患者免疫化疗中的作用。方法:临床药师参与1例滤泡性淋巴瘤合并丙型肝炎患者的药物治疗过程,建议先给予患者护肝、升白细胞、升血小板治疗,待肝功能、血象好转后行利妥昔单抗免疫化疗,治疗过程中需密切监测肝功能及丙型肝炎病毒核糖核酸(HCV-RNA)载量。在免疫化疗完成后,当患者淋巴瘤得到完全缓解后再考虑抗HCV治疗。结果:医师采纳临床药师建议,给予患者静脉滴注利妥昔单抗600 mg,治疗过程顺利,患者无特殊不适并出院。结论:临床药师参与患者个体化用药方案的制订,促进了医师的合理用药,进一步确保了患者用药安全。
ABSTRACT: OBJECTIVE: To explore the role of clinical pharmacists on immunochemotherapy for follicular lymphoma patients with hepatitis C. METHODS: Clinical pharmacists participated in the treatment process for a follicular lymphoma patient with hepatitis C. Clinical pharmacist suggested patient to initially take liver protection, white blood cell and platelet increasing therapy, and take rituximab immunochemotherapy after liver function and hemogram improved. During treatment, liver function and hepatitis C virus RNA (HCV-RNA) load should be monitored closely. After the completion of immunochemotherapy, the patient’s lymphoma was completely relieved and then anti-HCV treatment could be considered. RESULTS: Physicians adopted the suggestions of clinical pharmacists, and prescribed intravenous dripping of rituximab 600 mg to the patient. The immunochemotherapy was carried out smoothly, the patient didn’t feel discomfort and then discharged from hospital. CONCLUSIONS: The participation of clinical pharmacists in the formulation of individual medication plan, which promotes rational drug use and guarantee the safety of drug use.
期刊: 2018年第29卷第9期
作者: 徐姗,苏丹
AUTHORS: XU Shan,SU Dan
关键字: 临床药师;滤泡性淋巴瘤;丙型肝炎;免疫化疗;药学服务
KEYWORDS: Clinical pharmacist; Follicular lymphoma; Hepatitis C; Immunochemotherapy; Pharmaceutical care
阅读数: 250 次
本月下载数: 26 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!